EUVIMEDEUVIMED entdecken
Crossref

Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases

Xavier Boumaza, Margaux Lafaurie, Emmanuel Treiner, Ondine Walter, Gregory Pugnet, Guillaume Martin-Blondel, Damien Biotti, Jonathan Ciron, Arnaud Constantin, Marie Tauber, Florent Puisset, Guillaume Moulis und 4 weitere

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.110342 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Xavier Boumaza und 15 weiteren Autor:innen. Beteiligte Einrichtung: Service de Médecine Interne Purpan, Centre Hospitalier Universitaire de Toulouse, France; Service des Maladies Infectieuses et Tropicales, Centre Hos…. Hauptthemen laut MEDLINE: Agammaglobulinemia, Autoimmune Diseases, Arthritis, Rheumatoid, Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We conducted a single-centre retrospective cohort study in a French University Hospital between 2010 and 2018 to describe the risk of severe infectious event (SIE) within 2 years after the date of first rituximab infusion (T0) prescribed after the evidence of acquired hypogammaglobulinemia (gamma globulins [GG] ≤ 6 g/L) in the setting of autoimmune diseases (AID) other than rheumatoid arthritis. SIE occurred in 26 out of 121 included patients. Two years cumulative incidence rates were 12.7 % (95 % CI 5.1-23.9) in the multiple sclerosis/neuromyelitis optica spectrum disorder group (n = 48), 27.6 % (95 % CI 15.7-40.9) in the ANCA-associated vasculitis group (n = 48) and 30.6 % (95 % CI 13.1-50.3) in the 'other AID' group (n = 25). Median GG level at T0 was 5.3 g/l (IQR 4.1-5.6) in the 'SIE' group and 5.6 g/l (IQR 4.7-5.8) in the 'no SIE' group (p = 0.04). In regression analysis, risk of SIE increased with Charlson comorbidity index ≥ 3 (OR 2.77; 95 % CI 1.01-7.57), lung disease (OR 3.20; 95 % CI 1.27-7.99), GG < 4 g/L (OR 3.39; 95 % CI 1.02-11.19), concomitant corticosteroid therapy (OR 4.13; 95 % CI 1.63-10.44), previous cyclophosphamide exposure (OR 2.69; 95 % CI 1.10-6.61), a lymphocyte count < 1000 cells/µL (OR 2.86; 95 % CI 1.12-7.21) and absence of pneumococcal vaccination (OR 3.50; 95 % CI 1.41-8.70). These results may help to inform clinical decision when considering a treatment by rituximab in immunosuppressed AID patients with hypogammaglobulinemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AgammaglobulinemiaAutoimmune DiseasesArthritis, RheumatoidInfectionsHumansRituximabRetrospective Studies

Stichwörter der Autor:innen

HypogammaglobulinemiaInfectious riskRituximab

Substanzen

Rituximab

Autor:innen und Institutionen

  • Service de Médecine Interne Purpan, Centre Hospitalier Universitaire de Toulouse, France; Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse, France. Electronic address: boumaz…
  • Service de Pharmacologie Médicale et Clinique, Centre Hospitalier Universitaire de Toulouse, France; Centre d'Investigation Clinique 1436, Equipe PEPSS, Centre Hospitalier Universitaire de Toulouse, INSERM, Toulouse, Fr…
  • Laboratoire d'Immunologie, Institut Fédératif de Biologie, Centre Hospitalier Universitaire de Toulouse, France; Centre de Physiopathologie de Toulouse-Purpan, Centre Hospitalier Universitaire de Toulouse, France.
  • Service de Médecine Interne Purpan, Centre Hospitalier Universitaire de Toulouse, France; Centre d'Investigation Clinique 1436, Equipe PEPSS, Centre Hospitalier Universitaire de Toulouse, INSERM, Toulouse, France.
  • Service de Médecine Interne et immunologie clinique Rangueil, Centre Hospitalier Universitaire de, Toulouse, France.
  • Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051 - Universi…

Zitieren

APA

Boumaza, X., Lafaurie, M., Treiner, E., Walter, O., Pugnet, G., Martin-Blondel, G., Biotti, D., Ciron, J., Constantin, A., Tauber, M., Puisset, F., Moulis, G., Alric, L., Renaudineau, Y., Chauveau, D., & Sailler, L. (2023). Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110342

Vancouver

Boumaza X, Lafaurie M, Treiner E, Walter O, Pugnet G, Martin-Blondel G, et al. Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110342

BibTeX
@article{Boumaza2023,
  author = {Boumaza, Xavier and Lafaurie, Margaux and Treiner, Emmanuel and Walter, Ondine and Pugnet, Gregory and Martin-Blondel, Guillaume and Biotti, Damien and Ciron, Jonathan and Constantin, Arnaud and Tauber, Marie and Puisset, Florent and Moulis, Guillaume and Alric, Laurent and Renaudineau, Yves and Chauveau, Dominique and Sailler, Laurent},
  title = {Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.110342}
}
Kostenlos starten →